Waters Corporation (WAT) recently announced their Q3 2025 earnings conference call schedule and the corporation has been showing strong sales growth and raised guidance highlighted in its recent Q2 earnings call. The stock's performance has been a mix, with shares trading lower on some days and reporting an upward trend on others. In the past quarters, they have posted better-than-expected sales figures with optimistic quarterly revenue guidance. Amid these developments, the company is sealing a significant partnership with BD's Biosciences & Diagnostic Solutions Business, geared towards creating a life science and diagnostics leader focused on regulated, high-volume testing, which is a long-term play with certain risks. Moreover, their India business also appeared to get a boost thanks to a rush for weight-loss drugs. Waters Corp WAT, despite facing fluctuations, is positioned for growth due to an acquisition and strong financials while weighed down by merger focus and a valuation concern. Their growth potential is expected to be enhanced following the launch of their Xevo CDMS for mega-mass biomolecules and the proposed $17.5 Billion merger with BD Biosciences unit. However, concerns remain as the stock hit a 52-week low recently.
Waters Corp WAT News Analytics from Wed, 12 Feb 2025 08:00:00 GMT to Wed, 15 Oct 2025 14:34:25 GMT -
Rating 2
- Innovation 2
- Information 7
- Rumor -6
